Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NEPTUNUS Extension Study of Ianalumab in Sjögren's Syndrome
NCT05985915Phase 3Active, not recruiting
- Sponsor
- Novartis
- Start
- Oct 2023
- Primary completion
- Apr 2033
- Countries
- 35
01
Overview
A Phase 3 trial of ianalumab in Sjögren's syndrome, sponsored by Novartis. Started Oct 2023; status: active, not recruiting.
02
Drugs
ianalumab
03
Conditions
Sjögren's syndrome
Beyond the preview
Go deeper on NCT05985915.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05985915.